These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19996263)

  • 21. Reactivity of serotonin in whole blood.
    Mulder EJ; Anderson GM; Kema IP; Minderaa RB
    Biol Psychiatry; 2002 Feb; 51(3):266-8. PubMed ID: 11839371
    [No Abstract]   [Full Text] [Related]  

  • 22. [Obsessive compulsive disorder (OCD)].
    Debabèche C; Muselle A; Servais S; Farcy L; Barbier V; Laloyaux C; Mikolajczak G; Desseilles M
    Rev Med Suisse; 2009 Aug; 5(214):1659-62. PubMed ID: 19772197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study.
    Denys D; van Megen H; Westenberg H
    J Clin Psychiatry; 2002 Aug; 63(8):700-3. PubMed ID: 12197450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Remission rates in patients with anxiety disorders treated with paroxetine.
    Ballenger JC
    J Clin Psychiatry; 2004 Dec; 65(12):1696-707. PubMed ID: 15641876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Case study: caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder.
    Moore GJ; MacMaster FP; Stewart C; Rosenberg DR
    J Am Acad Child Adolesc Psychiatry; 1998 Jun; 37(6):663-7. PubMed ID: 9628087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The difference between obsessive-compulsive disorder in adolescence and in adults].
    Rabe-Jabłońska J
    Przegl Lek; 2001; 58 Suppl 3():11-4. PubMed ID: 11603169
    [No Abstract]   [Full Text] [Related]  

  • 28. Secondary obsessive-compulsive disorder related to diaschisis after pontine infarction, successfully treated with paroxetine.
    Matsui T; Saxena S; Kawabe J; Matsunaga H; Kohagura K; Higashiyama S; Kiriike N
    Psychiatry Clin Neurosci; 2007 Apr; 61(2):186-9. PubMed ID: 17362437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up of 85 patients with obsessive-compulsive disorder.
    Orloff LM; Battle MA; Baer L; Ivanjack L; Pettit AR; Buttolph ML; Jenike MA
    Am J Psychiatry; 1994 Mar; 151(3):441-2. PubMed ID: 8109659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of kleptomania with paroxetine.
    Kraus JE
    J Clin Psychiatry; 1999 Nov; 60(11):793. PubMed ID: 10584771
    [No Abstract]   [Full Text] [Related]  

  • 31. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial.
    Denys D; Van Nieuwerburgh F; Deforce D; Westenberg HG
    J Clin Psychiatry; 2007 May; 68(5):747-53. PubMed ID: 17503984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reactivity of serotonin in whole blood: relationship with drug response in obsessive-compulsive disorder.
    Humble M; Bejerot S; Bergqvist PB; Bengtsson F
    Biol Psychiatry; 2001 Feb; 49(4):360-8. PubMed ID: 11239907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paroxetine and obsessive-compulsive disorder.
    Kaye NS; Dancu C
    Am J Psychiatry; 1994 Oct; 151(10):1523. PubMed ID: 8092350
    [No Abstract]   [Full Text] [Related]  

  • 34. Obsessive compulsive disorder is not an anxiety disorder.
    Montgomery SA
    Int Clin Psychopharmacol; 1993 Sep; 8 Suppl 1():57-62. PubMed ID: 8254154
    [No Abstract]   [Full Text] [Related]  

  • 35. Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment.
    Tenneij NH; van Megen HJ; Denys DA; Westenberg HG
    J Clin Psychiatry; 2005 Sep; 66(9):1169-75. PubMed ID: 16187776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Eating disorders].
    Kiriike N
    Ryoikibetsu Shokogun Shirizu; 2003; (38):464-8. PubMed ID: 12877027
    [No Abstract]   [Full Text] [Related]  

  • 37. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial.
    Geller DA; Wagner KD; Emslie G; Murphy T; Carpenter DJ; Wetherhold E; Perera P; Machin A; Gardiner C
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1387-96. PubMed ID: 15502598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Venlafaxine in obsessive-compulsive disorder.
    Yaryura-Tobias JA; Neziroglu FA
    Arch Gen Psychiatry; 1996 Jul; 53(7):653-4. PubMed ID: 8660133
    [No Abstract]   [Full Text] [Related]  

  • 39. One year follow-up of postpartum-onset obsessive-compulsive disorder: a case series.
    Uguz F; Kaya N; Sahingoz M; Cilli AS; Akman C
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):1091-2. PubMed ID: 18400352
    [No Abstract]   [Full Text] [Related]  

  • 40. Paroxetine open-label treatment of pediatric outpatients with obsessive-compulsive disorder.
    Rosenberg DR; Stewart CM; Fitzgerald KD; Tawile V; Carroll E
    J Am Acad Child Adolesc Psychiatry; 1999 Sep; 38(9):1180-5. PubMed ID: 10504818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.